2
RESEARCH METHODOLOGY
39
5
MARKET OVERVIEW
Biopharmaceutical outsourcing surges amid rising biologics demand and cutting-edge manufacturing advancements.
60
5.2.1.1
INCREASING OUTSOURCING OF BIOLOGICS MANUFACTURING AMONG BIOPHARMACEUTICAL COMPANIES
5.2.1.2
RISING DEMAND FOR BIOLOGICS AND BIOSIMILARS
5.2.1.3
GROWING FOCUS ON PERSONALIZED MEDICINE
5.2.1.4
INCREASING COLLABORATIONS BETWEEN PHARMACEUTICAL COMPANIES AND BIOLOGICS CMOS
5.2.1.5
ADVANCEMENTS IN MANUFACTURING TECHNOLOGIES
5.2.2.1
INTELLECTUAL PROPERTY RIGHTS ISSUES
5.2.3.1
RISING DEMAND FOR CELL & GENE THERAPY
5.2.3.2
SIGNIFICANT GROWTH OPPORTUNITIES OFFERED BY EMERGING COUNTRIES
5.2.3.3
EXPANSION OF BIOLOGICS MANUFACTURING CAPACITIES BY CMOS
5.2.4.1
STRICT REGULATIONS
5.3.1.1
SINGLE-USE TECHNOLOGIES
5.3.1.2
CONTINUOUS BIOPROCESSING
5.3.2
COMPLEMENTARY TECHNOLOGIES
5.3.2.1
ROBOTICS AND AUTOMATION IN FILL-FINISH
5.3.2.2
CRISPR & GENE EDITING TOOLS
5.3.3
ADJACENT TECHNOLOGIES
5.3.3.1
3D BIOPRINTING & MICROFLUIDICS
5.3.3.2
BIOSENSORS & REAL-TIME ANALYTICS
5.4
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.5
PRICING ANALYSIS (QUALITATIVE)
5.9.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9.2
REGULATORY LANDSCAPE
5.10
KEY CONFERENCES & EVENTS, 2025–2026
5.11
PORTER’S FIVE FORCES ANALYSIS
5.11.1
THREAT OF NEW ENTRANTS
5.11.2
THREAT OF SUBSTITUTES
5.11.3
BARGAINING POWER OF SUPPLIERS
5.11.4
BARGAINING POWER OF BUYERS
5.11.5
INTENSITY OF COMPETITIVE RIVALRY
5.12
KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.13
INVESTMENT & FUNDING SCENARIO
5.14
IMPACT OF AI/GEN AI ON BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
5.15
IMPACT OF 2025 US TARIFFS ON BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
5.15.3
PRICE IMPACT ANALYSIS
5.15.4
IMPACT ON COUNTRY/REGION
5.15.5
IMPACT ON UPSTREAM INDUSTRIES
6
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 25 Data Tables
97
6.2.1
SHIFT TOWARD CONTINUOUSLY IMPROVING SINGLE-USE TECHNOLOGIES TO DRIVE MARKET
6.3
FORMULATION & FILL-FINISH
6.3.1
CRITICAL ROLE OF FORMULATION & FILL-FINISH IN BIOLOGICS MANUFACTURING TO DRIVE MARKET GROWTH
6.4.1
IMPORTANCE OF PACKAGING & LABELING IN ENSURING SAFETY AND EFFECTIVENESS TO SUPPORT MARKET GROWTH
7
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 13 Data Tables
112
7.2
BIOLOGIC DRUG SUBSTANCE MANUFACTURING
7.2.1
INCREASING DEMAND FOR BIOTECHNOLOGY PRODUCTS TO DRIVE MARKET
7.3
BIOLOGIC DRUG PRODUCT MANUFACTURING
7.3.1
INCREASING R&D COST AND PROCESS COMPLEXITY TO DRIVE DEMAND FOR CONTRACT MANUFACTURING FOR BIOLOGIC DRUG PRODUCTS
8
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 13 Data Tables
121
8.2
COMMERCIAL OPERATIONS
8.2.1
INCREASING APPROVALS OF BIOLOGICS TO SUPPORT MARKET GROWTH
8.3.1
INCREASING NUMBER OF CLINICAL TRIALS FOR TARGETED THERAPIES TO DRIVE MARKET
9
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 15 Data Tables
130
9.2
MAMMALIAN EXPRESSION SYSTEMS
9.2.1
VERSATILE THERAPEUTIC DIVERSITY OF MAMMALIAN EXPRESSION SYSTEMS TO DRIVE MARKET
9.3
NON-MAMMALIAN EXPRESSION SYSTEMS
9.3.1
INCREASING DEMAND FOR BIOLOGICS VACCINES TO SUPPORT MARKET GROWTH
10
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 41 Data Tables
140
10.2
MONOCLONAL ANTIBODIES
10.2.1
GROWING APPROVALS FOR MABS TO PROPEL MARKET
10.3.1
INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
10.4
ANTIBODY-DRUG CONJUGATES
10.4.1
INCREASING INVESTMENTS IN BIOLOGICS TO SUPPORT MARKET GROWTH
10.5.1
INCREASING DEMAND FOR VACCINES TO DRIVE MARKET
10.6
THERAPEUTIC PEPTIDES & PROTEINS
10.6.1
INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS TO SUPPORT MARKET GROWTH
11
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 43 Data Tables
163
11.2.1
INCREASED APPROVALS AND LAUNCH OF BIOLOGICS FOR ONCOLOGY TO DRIVE MARKET
11.3.1
RISING PREVALENCE OF AUTOIMMUNE DISEASES TO DRIVE MARKET
11.4
CARDIOVASCULAR DISEASES
11.4.1
DEVELOPMENT OF NEW TREATMENT OPTIONS TO SUPPORT MARKET GROWTH
11.5.1
INCREASING PREVALENCE OF METABOLIC DISEASES TO DRIVE ADOPTION OF BIOLOGICS
11.6.1
RISING EPIDEMIC OUTBREAKS TO SUPPORT MARKET GROWTH
11.7.1
HIGH BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
11.8
OTHER THERAPEUTIC AREAS
12
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 13 Countries | 168 Data Tables.
188
12.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2.1
PRESENCE OF LARGE NUMBER OF FDA-APPROVED MANUFACTURING FACILITIES TO FAVOR MARKET GROWTH
12.2.3.1
RISING GOVERNMENT FUNDING FOR DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH
12.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2.1
RAPIDLY GROWING PHARMACEUTICAL MARKET TO DRIVE MARKET
12.3.3.1
RISING INVESTMENTS IN DRUG DEVELOPMENT TO FAVOR MARKET GROWTH
12.3.4.1
AVAILABILITY OF FUNDS FROM GOVERNMENT AND PRIVATE ORGANIZATIONS FOR DOMESTIC DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH
12.3.5.1
RISING COMMERCIAL DRUG DEVELOPMENT PIPELINE TO DRIVE MARKET
12.3.6.1
RISING R&D EXPENDITURE TO PROPEL MARKET
12.3.7.1
STRONG R&D INVESTMENTS AND INFRASTRUCTURE EXPANSION TO BOLSTER BIOTECH MANUFACTURING
12.3.8.1
ROBUST R&D GROWTH AND CDMO CAPACITY EXPANSION TO FUEL PHARMA MANUFACTURING
12.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2.1
LOW MANUFACTURING COST AND HIGH DEMAND FOR MEDICINES TO FAVOR MARKET GROWTH
12.4.3.1
GROWING DEMAND FOR BIOSIMILARS TO DRIVE GROWTH
12.4.4.1
INCREASING PHARMA R&D ACTIVITIES AND GOVERNMENT FUNDING FOR BIOTECHNOLOGY INDUSTRY TO SUPPORT MARKET GROWTH
12.4.5.1
INCREASING R&D ACTIVITIES FOR DRUG DEVELOPMENT TO DRIVE MARKET
12.4.6
REST OF ASIA PACIFIC
12.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2.1
GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET
12.5.3.1
REGULATORY IMPROVEMENTS TO SUPPORT MARKET GROWTH
12.5.4
REST OF LATIN AMERICA
12.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST
12.6.2.1
SUBSTANTIAL OPPORTUNITIES FUELED BY STRONG GOVERNMENT SUPPORT TO BOOST GROWTH
12.6.3
REST OF MIDDLE EAST
12.7.1
EFFORTS TO IMPROVE LOCAL PHARMACEUTICAL PRODUCTION TO BOOST MARKET
12.7.2
MACROECONOMIC OUTLOOK FOR AFRICA
13
COMPETITIVE LANDSCAPE
Discover emerging leaders and strategies shaping the biopharmaceutical contract manufacturing landscape.
283
13.2
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2022−2025
13.3
REVENUE ANALYSIS, 2020–2024
13.4
MARKET SHARE ANALYSIS, 2024
13.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
13.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
13.5.5.1
COMPANY FOOTPRINT
13.5.5.2
REGION FOOTPRINT
13.5.5.3
SERVICE TYPE FOOTPRINT
13.5.5.4
MOLECULE TYPE FOOTPRINT
13.5.5.5
THERAPEUTIC AREA FOOTPRINT
13.6
COMPANY EVALUATION MATRIX: SMES/STARTUPS, 2024
13.6.1
PROGRESSIVE COMPANIES
13.6.2
RESPONSIVE COMPANIES
13.6.5
COMPETITIVE BENCHMARKING: SMES/STARTUPS, 2024
13.6.5.1
DETAILED LIST OF KEY SMES/STARTUPS
13.6.5.2
COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
13.7
COMPANY VALUATION & FINANCIAL METRICS
13.8
BRAND/PRODUCT COMPARISON
13.9
COMPETITIVE SCENARIO
14
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
304
14.1.1.1
BUSINESS OVERVIEW
14.1.1.2
SERVICES OFFERED
14.1.1.3
RECENT DEVELOPMENTS
14.1.1.4.2
STRATEGIC CHOICES
14.1.1.4.3
WEAKNESSES & COMPETITIVE THREATS
14.1.4
THERMO FISHER SCIENTIFIC INC.
14.1.7
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
14.1.8
FUJIFILM HOLDINGS CORPORATION
14.1.9
EUROFINS SCIENTIFIC
14.1.10
GENSCRIPT BIOTECH CORPORATION
14.1.15
AJINOMOTO BIO-PHARMA
14.1.16
AGILENT TECHNOLOGIES INC.
14.1.17
ASAHI KASEI CORPORATION
14.2.1
ONESOURCE PHARMA SOLUTIONS
14.2.3
EMERGENT BIOSOLUTIONS
14.2.4
SHANGHAI FOSUN PHARMACEUTICAL CO., LTD.
14.2.6
CURIA GLOBAL, INC.
14.2.7
POLYPLUS TRANSFECTION
14.2.9
MINAPHARM PHARMACEUTICALS
14.2.10
RENTSCHLER BIOPHARMA SE
14.2.11
PORTON PHARMA SOLUTIONS
14.2.13
MABPLEX INTERNATIONAL CO., LTD.
15.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3
CUSTOMIZATION OPTIONS
TABLE 1
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2
IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
TABLE 3
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RISK ANALYSIS
TABLE 4
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 5
LIST OF KEY BIOSIMILARS APPROVED, 2023–2025
TABLE 6
LIST OF EXPANSIONS BY TOP COMPANIES
TABLE 7
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ROLE IN ECOSYSTEM
TABLE 8
NUMBER OF PATENTS FILED IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2014–2024
TABLE 9
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: INDICATIVE LIST OF PATENTS, 2022
TABLE 10
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14
COUNTRY-WISE REGULATORY SCENARIO FOR CONTRACT MANUFACTURING
TABLE 15
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2025–2026)
TABLE 16
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 17
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING SERVICES (%)
TABLE 18
KEY BUYING CRITERIA FOR BIOPHARMACEUTICAL CONTRACT MANUFACTURING SERVICES, BY END USER
TABLE 19
US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 20
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 21
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD MILLION)
TABLE 22
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 23
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 24
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 25
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 26
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD MILLION)
TABLE 27
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY REGION, 2023–2030 (USD MILLION)
TABLE 28
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 29
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 30
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 31
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 32
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY REGION, 2023–2030 (USD MILLION)
TABLE 33
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY REGION, 2023–2030 (USD MILLION)
TABLE 34
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 35
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 36
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 37
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 38
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY REGION, 2023–2030 (USD MILLION)
TABLE 39
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD MILLION)
TABLE 40
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 41
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 42
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 43
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 44
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD MILLION)
TABLE 45
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 46
BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 47
NORTH AMERICA: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 48
EUROPE: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 49
ASIA PACIFIC: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 50
LATIN AMERICA: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 51
MIDDLE EAST: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 52
BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 53
NORTH AMERICA: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 54
EUROPE: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 55
ASIA PACIFIC: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 56
LATIN AMERICA: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 57
MIDDLE EAST: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 58
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 59
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 60
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 61
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 62
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 63
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 64
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 65
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 66
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 67
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 68
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 69
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 70
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 71
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 72
TYPES OF MAMMALIAN EXPRESSION SYSTEMS
TABLE 73
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD MILLION)
TABLE 74
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 75
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 76
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 77
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 78
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD MILLION)
TABLE 79
TYPES OF MICROBIAL EXPRESSION SYSTEMS AND THEIR APPLICATIONS
TABLE 80
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD MILLION)
TABLE 81
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 82
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 83
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 84
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD MILLION)
TABLE 86
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 87
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 88
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 89
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 90
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 91
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 92
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 93
FDA-APPROVED CAR T-CELL THERAPIES
TABLE 94
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY REGION, 2023–2030 (USD MILLION)
TABLE 95
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 96
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 97
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 98
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 99
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY REGION, 2023–2030 (USD MILLION)
TABLE 100
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY REGION, 2023–2030 (USD MILLION)
TABLE 101
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 102
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 103
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 104
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 105
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY REGION, 2023–2030 (USD MILLION)
TABLE 106
NIH FUNDING FOR VACCINE RESEARCH, 2018–2024 (USD MILLION)
TABLE 107
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY REGION, 2023–2030 (USD MILLION)
TABLE 108
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 109
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 110
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 111
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY REGION, 2023–2030 (USD MILLION)
TABLE 113
EXAMPLES OF PEPTIDE THERAPEUTICS
TABLE 114
COMMERCIALIZED RECOMBINANT PROTEINS USED IN MEDICINE
TABLE 115
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2023–2030 (USD MILLION)
TABLE 116
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 117
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 118
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 120
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2023–2030 (USD MILLION)
TABLE 121
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION)
TABLE 122
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 123
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 124
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 125
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 126
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION)
TABLE 127
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 128
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 129
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 130
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 131
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 132
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 133
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 134
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 135
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 136
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 137
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 138
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 139
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 140
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 141
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 142
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 143
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 144
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 145
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 146
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 147
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 148
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 149
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 150
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 151
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 152
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 153
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 154
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 155
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 156
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 157
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 158
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 159
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 160
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 161
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 162
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 163
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY REGION 2023–2030 (USD MILLION)
TABLE 164
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)
TABLE 165
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 166
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 167
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 168
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 169
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)
TABLE 170
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 171
NORTH AMERICA: KEY MACROINDICATORS
TABLE 172
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 173
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 174
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 175
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 176
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 177
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 178
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 179
US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 180
US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 181
US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 182
US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 183
US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 184
US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 185
CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 186
CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 187
CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 188
CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 189
CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 190
CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 191
EUROPE: KEY MACROINDICATORS
TABLE 192
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 193
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 194
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 195
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 196
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 197
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 198
EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 199
GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 200
GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 201
GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 202
GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 203
GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 204
GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 205
UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 206
UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 207
UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 208
UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 209
UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 210
UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 211
FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 212
FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 213
FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 214
FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 215
FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 216
FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 217
ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 218
ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 219
ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 220
ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 221
ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 222
ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 223
SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 224
SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 225
SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 226
SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 227
SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 228
SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 229
SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 230
SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 231
SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 232
SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 233
SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 234
SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 235
IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 236
IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 237
IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 238
IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 239
IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 240
IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 241
REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 242
REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 243
REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 244
REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 245
REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 246
REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 247
ASIA PACIFIC: KEY MACROINDICATORS
TABLE 248
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 249
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 250
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 251
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 252
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 253
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 254
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 255
CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 256
CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 257
CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 258
CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 259
CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 260
CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 261
JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 262
JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 263
JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 264
JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 265
JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 266
JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 267
INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 268
INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 269
INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 270
INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 271
INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 272
INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 273
SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 274
SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 275
SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 276
SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 277
SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 278
SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 279
REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 280
REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 281
REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 282
REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 283
REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 284
REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 285
LATIN AMERICA: KEY MACROINDICATORS
TABLE 286
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 287
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 288
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 289
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 290
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 291
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 292
LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 293
BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 294
BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 295
BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 296
BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 297
BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 298
BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 299
MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 300
MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 301
MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 302
MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 303
MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 304
MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 305
REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 306
REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 307
REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 308
REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 309
REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 310
REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 311
MIDDLE EAST: KEY MACROINDICATORS
TABLE 312
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 313
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 314
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 315
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 316
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 317
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 318
MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 319
GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 320
GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 321
GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 322
GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 323
GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 324
GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 325
REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 326
REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 327
REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 328
REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 329
REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 330
REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 331
AFRICA: KEY MACROINDICATORS
TABLE 332
AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
TABLE 333
AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 334
AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
TABLE 335
AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
TABLE 336
AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
TABLE 337
AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 338
STRATEGIES DEPLOYED BY KEY PLAYERS
TABLE 339
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DEGREE OF COMPETITION
TABLE 340
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: REGION FOOTPRINT
TABLE 341
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE TYPE FOOTPRINT
TABLE 342
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: MOLECULE TYPE FOOTPRINT
TABLE 343
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: THERAPEUTIC AREA FOOTPRINT
TABLE 344
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DETAILED LIST OF KEY SMES/STARTUPS
TABLE 345
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, 2024
TABLE 346
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE LAUNCHES, JANUARY 2022–JUNE 2025
TABLE 347
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DEALS, JANUARY 2022–JUNE 2025
TABLE 348
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: EXPANSIONS, JANUARY 2022– JUNE 2025
TABLE 349
LONZA: COMPANY OVERVIEW
TABLE 350
LONZA: SERVICES OFFERED
TABLE 351
LONZA: DEALS, JANUARY 2022–JUNE 2025
TABLE 352
LONZA: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 353
WUXI BIOLOGICS: COMPANY OVERVIEW
TABLE 354
WUXI BIOLOGICS: SERVICES OFFERED
TABLE 355
WUXI BIOLOGICS: DEALS, JANUARY 2022–JUNE 2025
TABLE 356
WUXI BIOLOGICS: EXPANSIONS, JANUARY 2022– JUNE 2025
TABLE 357
SAMSUNG BIOLOGICS: COMPANY OVERVIEW
TABLE 358
SAMSUNG BIOLOGICS: SERVICES OFFERED
TABLE 359
SAMSUNG BIOLOGICS: SERVICE LAUNCHES, JANUARY 2022–JUNE 2025
TABLE 360
SAMSUNG BIOLOGICS: DEALS, JANUARY 2022–JUNE 2025
TABLE 361
SAMSUNG BIOLOGICS: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 362
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 363
THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED
TABLE 364
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–JUNE 2025
TABLE 365
ABBVIE INC.: COMPANY OVERVIEW
TABLE 366
ABBVIE INC.: SERVICES OFFERED
TABLE 367
CATALENT, INC.: COMPANY OVERVIEW
TABLE 368
CATALENT, INC.: SERVICES OFFERED
TABLE 369
CATALENT, INC.: DEALS, JANUARY 2022–JUNE 2025
TABLE 370
CATALENT, INC.: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 371
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
TABLE 372
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SERVICES OFFERED
TABLE 373
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025
TABLE 374
FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW
TABLE 375
FUJIFILM HOLDINGS CORPORATION: SERVICES OFFERED
TABLE 376
FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2022–JUNE 2025
TABLE 377
FUJIFILM HOLDINGS CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 378
EUROFINS SCIENTIFIC: COMPANY OVERVIEW
TABLE 379
EUROFINS SCIENTIFIC: SERVICES OFFERED
TABLE 380
EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 381
GENSCRIPT BIOTECH CORPORATION: COMPANY OVERVIEW
TABLE 382
GENSCRIPT BIOTECH CORPORATION: SERVICES OFFERED
TABLE 383
GENSCRIPT BIOTECH CORPORATION: SERVICE LAUNCHES, JANUARY 2022–JUNE 2025
TABLE 384
GENSCRIPT BIOTECH CORPORATION: DEALS, JANUARY 2022–JUNE 2025
TABLE 385
GENSCRIPT BIOTECH CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 386
ACG INC.: COMPANY OVERVIEW
TABLE 387
AGC INC.: SERVICES OFFERED
TABLE 388
AGC INC: DEALS, JANUARY 2022–JUNE 2025
TABLE 389
AGC INC.: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 390
MERCK KGAA: COMPANY OVERVIEW
TABLE 391
MERCK KGAA: SERVICES OFFERED
TABLE 392
MERCK KGAA: DEALS, JANUARY 2022–JUNE 2025
TABLE 393
MERCK KGAA: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 394
JSR CORPORATION: COMPANY OVERVIEW
TABLE 395
JSR CORPORATION: SERVICES OFFERED
TABLE 396
JSR CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 397
IDT BIOLOGIKA: COMPANY OVERVIEW
TABLE 398
IDT BIOLOGIKA: SERVICES OFFERED
TABLE 399
IDT BIOLOGIKA: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025
TABLE 400
AJINOMOTO BIO-PHARMA: COMPANY OVERVIEW
TABLE 401
AJINOMOTO BIO-PHARMA: SERVICES OFFERED
TABLE 402
AJINOMOTO BIO-PHARMA: DEALS, JANUARY 2022–JUNE 2025
TABLE 403
AGILENT TECHNOLOGIES INC.: COMPANY OVERVIEW
TABLE 404
AGILENT TECHNOLOGIES INC.: SERVICES OFFERED
TABLE 405
AGILENT TECHNOLOGIES INC.: DEALS, JANUARY 2022–JUNE 2025
TABLE 406
ASAHI KASEI CORPORATION: COMPANY OVERVIEW
TABLE 407
ASAHI KASEI CORPORATION: SERVICES OFFERED
TABLE 408
ASAHI KASEI CORPORATION: DEALS, JANUARY 2022–JUNE 2025
TABLE 409
ONESOURCE PHARMA SOLUTIONS: COMPANY OVERVIEW
TABLE 410
RECIPHARM AB: COMPANY OVERVIEW
TABLE 411
EMERGENT: COMPANY OVERVIEW
TABLE 412
SHANGHAI FOSUN PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW
TABLE 413
LOTTE BIOLOGICS: COMPANY OVERVIEW
TABLE 414
CURIA GLOBAL, INC.: COMPANY OVERVIEW
TABLE 415
POLYPLUS TRANSFECTION: COMPANY OVERVIEW
TABLE 416
ALDEVRON LLC: COMPANY OVERVIEW
TABLE 417
MINAPHARM PHARMACEUTICALS: COMPANY OVERVIEW
TABLE 418
RENTSCHLER BIOPHARMA SE: COMPANY OVERVIEW
TABLE 419
PORTON PHARMA SOLUTIONS: COMPANY OVERVIEW
TABLE 420
CELLARES, INC.: COMPANY OVERVIEW
TABLE 421
MABPLEX INTERNATIONAL CO., LTD.: COMPANY OVERVIEW
TABLE 422
ASYMCHEM INC.: COMPANY OVERVIEW
FIGURE 1
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: YEARS CONSIDERED
FIGURE 3
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RESEARCH DESIGN
FIGURE 4
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY DATA FROM SECONDARY SOURCES
FIGURE 5
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 6
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
FIGURE 7
COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH (2024)
FIGURE 8
REVENUE SHARE ANALYSIS OF THERMO FISHER SCIENTIFIC INC. (2024)
FIGURE 9
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 10
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: TOP-DOWN APPROACH
FIGURE 11
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: CAGR PROJECTIONS
FIGURE 12
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DATA TRIANGULATION
FIGURE 13
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2025 VS. 2030 (USD MILLION)
FIGURE 14
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
FIGURE 15
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2025 VS. 2030 (USD MILLION)
FIGURE 16
GEOGRAPHICAL SNAPSHOT OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FIGURE 17
INCREASING APPROVALS OF BIOLOGICS TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
FIGURE 18
COMMERCIAL OPERATIONS SEGMENT TO ACCOUNT FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2025
FIGURE 19
ONCOLOGY SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2030
FIGURE 20
MONOCLONAL ANTIBODIES TO CONTINUE TO DOMINATE MARKET IN 2030
FIGURE 21
ASIA PACIFIC TO BE FASTEST-GROWING MARKET IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET DURING FORECAST PERIOD
FIGURE 22
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 23
PERSONALIZED MEDICINES (% OF ALL FDA-APPROVED DRUGS), 2015–2024
FIGURE 24
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 25
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: VALUE CHAIN ANALYSIS
FIGURE 26
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ECOSYSTEM MAP
FIGURE 27
PATENT ANALYSIS OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, JANUARY 2014–DECEMBER 2024
FIGURE 28
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 29
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING SERVICES
FIGURE 30
KEY BUYING CRITERIA FOR BIOPHARMACEUTICAL CONTRACT MANUFACTURING SERVICES, BY END USER
FIGURE 31
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: INVESTMENT & FUNDING SCENARIO
FIGURE 32
NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT
FIGURE 33
ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT
FIGURE 34
REVENUE ANALYSIS OF KEY PLAYERS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2020–2024 (USD MILLION)
FIGURE 35
MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET (2024)
FIGURE 36
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 37
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY FOOTPRINT
FIGURE 38
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (SMES/STARTUPS), 2024
FIGURE 39
EV/EBITDA OF KEY VENDORS
FIGURE 40
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 41
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 42
LONZA: COMPANY SNAPSHOT (2024)
FIGURE 43
WUXI BIOLOGICS: COMPANY SNAPSHOT (2024)
FIGURE 44
SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2024)
FIGURE 45
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
FIGURE 46
ABBVIE INC.: COMPANY SNAPSHOT (2024)
FIGURE 47
CATALENT, INC.: COMPANY SNAPSHOT (2024)
FIGURE 48
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2024)
FIGURE 49
FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 50
EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)
FIGURE 51
SGENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 52
AGC INC.: COMPANY SNAPSHOT (2024)
FIGURE 53
MERCK KGAA: COMPANY SNAPSHOT (2024)
FIGURE 54
JSR CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 55
AJINOMOTO BIO-PHARMA: COMPANY SNAPSHOT (2024)
FIGURE 56
AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2024)
FIGURE 57
ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2024)
Growth opportunities and latent adjacency in Biopharmaceutical Contract Manufacturing Market